Andrzej Kułach1, Milena Dewerenda2, Michał Majewski3, Anetta Lasek-Bal4, Zbigniew Gąsior1. 1. Department of Cardiology, Medical University of Silesia, 40-635 Katowice, Poland. 2. Upper-Silesian Medical Center, Department of Neurology, 40-635 Katowice, Poland. 3. Upper-Silesian Medical Center, Department of Cardiology, 40-635 Katowice, Poland. 4. Department of Neurology, Medical University of Silesia, 40-635 Katowice, Poland.
Abstract
INTRODUCTION: Silent atrial fibrillation (AF) is a common cause of cryptogenic ischemic stroke (CIS). The 24-h-Holter is insufficient to reveal an occult arrhythmic cause of stroke and the strategy to select the patients for long-term monitoring is missing. OBJECTIVES: The aim of the study was to evaluate 7-day-Holter monitoring to identify cases with the arrhythmic cause of stroke in CIS patients in whom 24-h-Holter was free from arrhythmia, and to assess the relation between supraventricular (SV) runs in baseline Holter and the incidence of AF in a 3-year follow-up period. METHODS: 78 patients (aged 60 ± 9 years, 45 males) with CIS and no arrhythmic findings in 24-h-Holter were enrolled. All patients had 7-day-Holter monitoring after stroke and were followed up for 36 months, and then 7-day Holter was repeated. We assessed SV runs (≥5 QRS) in the initial 7-day Holter and analyzed the relation of the findings with clinical characteristics of novel AF episodes revealed early after stroke and during a 3-year follow-up. RESULTS: Baseline 7-day-Holter revealed SV runs in 36% of patients and AF in 9% of cases. During a 3-year follow-up, 8 additional cases were confirmed, both in standard care and in repeated Holter (a total of 19% of AF cases). There was no difference with regard to CHADS2VASc score (3.6 ± 1.1 vs. 3.4 ± 1.5; p = NS) and left atrium parameters between patients with SV runs and the non-arrhythmic group. Patients with SV runs had a higher incidence of AF both after stroke and in a 3-year follow-up (46% vs. 4%, RR 11.6, p < 0.001). In 8 cases, patent foramen ovale was detected during follow-up. CONCLUSIONS: A strategy of baseline 7-day-Holter monitoring after stroke allows for disclosing SV runs in every third case and AF in 9% of stroke survivors. Patients with SV runs have a higher incidence of AF (RR 11.6, p < 0.001) and should be considered for extended continuous ECG monitoring.
INTRODUCTION:Silent atrial fibrillation (AF) is a common cause of cryptogenic ischemic stroke (CIS). The 24-h-Holter is insufficient to reveal an occult arrhythmic cause of stroke and the strategy to select the patients for long-term monitoring is missing. OBJECTIVES: The aim of the study was to evaluate 7-day-Holter monitoring to identify cases with the arrhythmic cause of stroke in CIS patients in whom 24-h-Holter was free from arrhythmia, and to assess the relation between supraventricular (SV) runs in baseline Holter and the incidence of AF in a 3-year follow-up period. METHODS: 78 patients (aged 60 ± 9 years, 45 males) with CIS and no arrhythmic findings in 24-h-Holter were enrolled. All patients had 7-day-Holter monitoring after stroke and were followed up for 36 months, and then 7-day Holter was repeated. We assessed SV runs (≥5 QRS) in the initial 7-day Holter and analyzed the relation of the findings with clinical characteristics of novel AF episodes revealed early after stroke and during a 3-year follow-up. RESULTS: Baseline 7-day-Holter revealed SV runs in 36% of patients and AF in 9% of cases. During a 3-year follow-up, 8 additional cases were confirmed, both in standard care and in repeated Holter (a total of 19% of AF cases). There was no difference with regard to CHADS2VASc score (3.6 ± 1.1 vs. 3.4 ± 1.5; p = NS) and left atrium parameters between patients with SV runs and the non-arrhythmic group. Patients with SV runs had a higher incidence of AF both after stroke and in a 3-year follow-up (46% vs. 4%, RR 11.6, p < 0.001). In 8 cases, patent foramen ovale was detected during follow-up. CONCLUSIONS: A strategy of baseline 7-day-Holter monitoring after stroke allows for disclosing SV runs in every third case and AF in 9% of stroke survivors. Patients with SV runs have a higher incidence of AF (RR 11.6, p < 0.001) and should be considered for extended continuous ECG monitoring.
Authors: Paul D Ziegler; Taya V Glotzer; Emile G Daoud; Daniel E Singer; Michael D Ezekowitz; Robert H Hoyt; Jodi L Koehler; James Coles; D George Wyse Journal: Am J Cardiol Date: 2012-07-20 Impact factor: 2.778
Authors: Jeff S Healey; Stuart J Connolly; Michael R Gold; Carsten W Israel; Isabelle C Van Gelder; Alessandro Capucci; C P Lau; Eric Fain; Sean Yang; Christophe Bailleul; Carlos A Morillo; Mark Carlson; Ellison Themeles; Elizabeth S Kaufman; Stefan H Hohnloser Journal: N Engl J Med Date: 2012-01-12 Impact factor: 91.245
Authors: David J Gladstone; Paul Dorian; Melanie Spring; Val Panzov; Muhammad Mamdani; Jeff S Healey; Kevin E Thorpe Journal: Stroke Date: 2015-02-19 Impact factor: 7.914
Authors: Tommaso Sanna; Hans-Christoph Diener; Rod S Passman; Vincenzo Di Lazzaro; Richard A Bernstein; Carlos A Morillo; Marilyn Mollman Rymer; Vincent Thijs; Tyson Rogers; Frank Beckers; Kate Lindborg; Johannes Brachmann Journal: N Engl J Med Date: 2014-06-26 Impact factor: 91.245
Authors: Hooman Kamel; Mitchell S V Elkind; Prashant D Bhave; Babak B Navi; Peter M Okin; Costantino Iadecola; Richard B Devereux; Matthew E Fink Journal: Stroke Date: 2013-04-30 Impact factor: 7.914
Authors: Robert G Hart; Hans-Christoph Diener; Shelagh B Coutts; J Donald Easton; Christopher B Granger; Martin J O'Donnell; Ralph L Sacco; Stuart J Connolly Journal: Lancet Neurol Date: 2014-04 Impact factor: 44.182
Authors: Gerhard Hindricks; Tatjana Potpara; Nikolaos Dagres; Elena Arbelo; Jeroen J Bax; Carina Blomström-Lundqvist; Giuseppe Boriani; Manuel Castella; Gheorghe-Andrei Dan; Polychronis E Dilaveris; Laurent Fauchier; Gerasimos Filippatos; Jonathan M Kalman; Mark La Meir; Deirdre A Lane; Jean-Pierre Lebeau; Maddalena Lettino; Gregory Y H Lip; Fausto J Pinto; G Neil Thomas; Marco Valgimigli; Isabelle C Van Gelder; Bart P Van Putte; Caroline L Watkins Journal: Eur Heart J Date: 2021-02-01 Impact factor: 29.983
Authors: Linxin Li; Gabriel S Yiin; Olivia C Geraghty; Ursula G Schulz; Wilhelm Kuker; Ziyah Mehta; Peter M Rothwell Journal: Lancet Neurol Date: 2015-07-27 Impact factor: 59.935
Authors: Marta Rubiera; Ana Aires; Kateryna Antonenko; Sabrina Lémeret; Christian H Nolte; Jukka Putaala; Renate B Schnabel; Anil M Tuladhar; David J Werring; Dena Zeraatkar; Maurizio Paciaroni Journal: Eur Stroke J Date: 2022-06-03